<table id="_Reftable9" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Results of Drug Interaction Studies with VIDEX EC: Effects of Coadministered Drug on Didanosine Plasma AUC and C<sub>max</sub> Values</caption>
<col width="34%"></col>
<col width="29%"></col>
<col width="8%"></col>
<col width="14%"></col>
<col width="14%"></col>
<thead>
<tr>
<th align="left" stylecode="Toprule " valign="top"></th>
<th align="left" stylecode="Toprule " valign="top"></th>
<th align="left" stylecode="Toprule " valign="top"></th>
<th align="center" colspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">% Change of Didanosine</content>
<br/>
<content stylecode="bold">Pharmacokinetic Parameters<sup>a</sup>
</content>
</th>
</tr>
<tr>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">Drug</content>
</th>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">Didanosine Dosage</content>
</th>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">n</content>
</th>
<th align="center" stylecode="Botrule " valign="top">
<content stylecode="bold">AUC of </content>
<br/>
<content stylecode="bold">Didanosine</content>
<br/>
<content stylecode="bold">(90% CI)</content>
</th>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">C<sub>max</sub> of </content>
<br/>
<content stylecode="bold">Didanosine</content>
<br/>
<content stylecode="bold">(90% CI)</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="5" stylecode="Botrule" valign="top">↑ Indicates increase.<br/>↓ Indicates decrease.<br/>↔ Indicates no change, or mean increase or decrease of less than 10%.<br/>
<sup>a</sup>  The 90% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.<br/>
<sup>b</sup>  All studies conducted in healthy volunteers at least 60 kg with creatinine clearance of at least 60 mL/min.<br/>
<sup>c</sup>  Tenofovir disoproxil fumarate.<br/>
<sup>d</sup>  373 kcalories, 8.2 grams fat.<br/>
<sup>e</sup>  Compared with VIDEX EC 250 mg administered alone under fasting conditions.<br/>
<sup>f</sup>  Compared with VIDEX EC 400 mg administered alone under fasting conditions.<br/>
<sup>g</sup>  Comparisons are made to historical controls (n=148, pooled from 5 studies) conducted in healthy subjects. The number of subjects evaluated for AUC and C<sub>max</sub> is 15 and 16, respectively.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Toprule ">
<paragraph>
<content stylecode="bold">tenofovir</content>,<sup>b,c</sup> 300 mg<br/>  once daily with a light meal<sup>d</sup>
</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>400 mg single dose fasting<br/>2 hours before tenofovir</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>26</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>↑ 48%<br/>(31, 67%)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>↑ 48%<br/>(25, 76%)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<content stylecode="bold">tenofovir</content>,<sup>b,c</sup> 300 mg<br/>  once daily with a light meal<sup>d</sup>
</paragraph>
</td>
<td align="center">
<paragraph>400 mg single dose<br/>with tenofovir and a light meal</paragraph>
</td>
<td align="center">
<paragraph>25</paragraph>
</td>
<td align="center">
<paragraph>↑ 60%<br/>(44, 79%)</paragraph>
</td>
<td align="center">
<paragraph>↑ 64%<br/>(41, 89%)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<content stylecode="bold">tenofovir</content>,<sup>b,c</sup> 300 mg<br/>  once daily with a light meal<sup>d</sup>
</paragraph>
</td>
<td align="center">
<paragraph>200 mg single dose<br/>with tenofovir and a light meal</paragraph>
</td>
<td align="center">
<paragraph>33</paragraph>
</td>
<td align="center">
<paragraph>↑ 16%<br/>(6, 27%)<sup>e</sup>
</paragraph>
</td>
<td align="center">
<paragraph>↓ 12%<br/>(-25, 3%)<sup>e</sup>
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph> </paragraph>
</td>
<td align="center">
<paragraph>250 mg single dose<br/>with tenofovir and a light meal</paragraph>
</td>
<td align="center">
<paragraph>33</paragraph>
</td>
<td align="center">
<paragraph>↔ <br/>(-13, 5%)<sup>f</sup>
</paragraph>
</td>
<td align="center">
<paragraph>↓ 20%<br/>(-32, -7%)<sup>f</sup>
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph> </paragraph>
</td>
<td align="center">
<paragraph>325 mg single dose<br/>with tenofovir and a light meal</paragraph>
</td>
<td align="center">
<paragraph>33</paragraph>
</td>
<td align="center">
<paragraph>↑ 13%<br/>(3, 24%)<sup>f</sup>
</paragraph>
</td>
<td align="center">
<paragraph>↓ 11%<br/>(-24, 4%)<sup>f</sup>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>
<content stylecode="bold">methadone</content>, chronic maintenance dose </paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>400 mg single dose</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>15, 16<sup>g</sup>
</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>↓ 17%<br/>(-29, -2%)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>↓ 16%<br/>(-33, 4%)</paragraph>
</td>
</tr>
</tbody>
</table>